Académique Documents
Professionnel Documents
Culture Documents
Clinical Manifestation
Neuropsychological
symptoms:
It
is
crucial
to
evaluate
the
impact
of
FM
symptoms
on
function
and
role
fulfilment.
In
defining
the
success
of
a
1. Fatigue
management
strategy,
improved
function
is
a
key
2. Stiffness
measure.
Functional
assessment
should
include
3. Sleep
disturbance
physical,
mental,
and
social
domains.
4. Cognitive
dysfunction
5. Anxiety
and
depression
Differential
Diagnosis
1. Headaches
Infectious
2. Facial/jaw
pain
Hepatitis
C
3. Regional
myofascial
pain
particularly
involving
the
neck
or
back.
Human
immunodeficiency
virus
(HIV)
4. Arthritis.
Lyme
disease
Visceral
Pain
Parvovirus
B19
1. Gastrointestinal
tract
2. Bladder,
pelvic
and
perineal
pain.
Epstein-‐Barr
virus
*Patients
may
or
may
not
meet
defined
criteria
for
specific
syndromes.
Noninflammatory
FM
often
has
their
onset
and
is
exacerbated
during
Hypo-‐
or
hyperthyroidism
periods
of
high
levels
of
real
or
perceived
stress.
This
Hyperparathyroidism
may
reflect
an
interaction
between
central
stress
physiology,
vigilance
or
anxiety,
and
central
pain-‐ Neurologic
diseases
processing
pathways.
July
5,
2012
[FIBROMYALGIA]
Multiple
sclerosis
controlling
pain
sensitivity
and
stress
response.
Some
of
the
genetic
underpinnings
of
FM
are
shared
across
Neuropathic
pain
syndromes
other
chronic
pain
conditions.
Drugs
Non
pharma;
Statins
1. The
physician
should
focus
on
improved
Aromatase
inhibitors
function
and
quality
of
life
rather
than
elimination
of
pain.
2. Physical
conditioning,
with
encouragement
to
Laboratory
and
radiographic
testing
begin
at
low
levels
of
aerobic
exercise
with
slow
but
consistent
advancement.
3. Patients
who
have
been
physically
inactive
or
Routine
who
report
post-‐exertional
malaise
may
do
best
Erythrocyte
sedimentation
rate
(ESR)
and
C-‐ in
supervised
or
water-‐based
programs
to
start.
reactive
protein
(CRP)
4. Yoga
and
Tai
Chi
may
also
be
helpful.
5. Strength
training.
Complete
blood
count
(CBC)
6. Cognitive
behavioural
strategies.
a
Genetics
and
Physiology
Approved
for
fibromyalgia
by
the
U.S.
Food
and
Drug
Administration.
As
in
most
complex
diseases,
it
is
likely
that
a
number
of
genes
contribute
to
vulnerability
to
the
development
of
FM.
To
date,
these
genes
appear
to
be
in
pathways
July
5,
2012
[FIBROMYALGIA]
Additional
Notes:
Adhesive
capsulitis
Calcific tendinitis
Etiology:
s/sx
Finkelstein sign